JP2004536847A - 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法 - Google Patents

眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法 Download PDF

Info

Publication number
JP2004536847A
JP2004536847A JP2003511808A JP2003511808A JP2004536847A JP 2004536847 A JP2004536847 A JP 2004536847A JP 2003511808 A JP2003511808 A JP 2003511808A JP 2003511808 A JP2003511808 A JP 2003511808A JP 2004536847 A JP2004536847 A JP 2004536847A
Authority
JP
Japan
Prior art keywords
eye
combretastatin
subject
administered
ocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003511808A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004536847A5 (enExample
Inventor
デイビッド シェリス，
マーク ウッド，
Original Assignee
オキシジーン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オキシジーン， インコーポレイテッド filed Critical オキシジーン， インコーポレイテッド
Publication of JP2004536847A publication Critical patent/JP2004536847A/ja
Publication of JP2004536847A5 publication Critical patent/JP2004536847A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2003511808A 2001-07-13 2002-07-15 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法 Pending JP2004536847A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38622701P 2001-07-13 2001-07-13
US37755602P 2002-05-03 2002-05-03
US37784502P 2002-05-03 2002-05-03
US37784702P 2002-05-03 2002-05-03
PCT/US2002/022449 WO2003006002A1 (en) 2001-07-13 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009063664A Division JP2009132738A (ja) 2001-07-13 2009-03-16 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2004536847A true JP2004536847A (ja) 2004-12-09
JP2004536847A5 JP2004536847A5 (enExample) 2006-01-05

Family

ID=32034390

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003511808A Pending JP2004536847A (ja) 2001-07-13 2002-07-15 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法
JP2009063664A Pending JP2009132738A (ja) 2001-07-13 2009-03-16 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009063664A Pending JP2009132738A (ja) 2001-07-13 2009-03-16 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法

Country Status (8)

Country Link
EP (1) EP1406600A4 (enExample)
JP (2) JP2004536847A (enExample)
KR (1) KR20040030042A (enExample)
CN (1) CN1527704B (enExample)
CA (1) CA2453442C (enExample)
NZ (1) NZ575466A (enExample)
WO (1) WO2003006002A1 (enExample)
ZA (1) ZA200400210B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532113A (ja) * 2009-07-02 2012-12-13 オキシジーン， インコーポレイテッド 後嚢混濁を予防するためのコンブレタスタチン
JP2013502440A (ja) * 2009-08-27 2013-01-24 バイオノミックス リミテッド 黄斑変性の治療

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
JP4005048B2 (ja) * 2003-04-09 2007-11-07 日信工業株式会社 炭素繊維複合材料およびその製造方法
NZ598489A (en) 2009-08-27 2014-03-28 Bionomics Ltd Combination therapy for treating proliferative diseases
CN104619760B (zh) * 2012-08-02 2016-10-26 阿米利尔股份公司 含纳米碳的天然橡胶
CN113577020B (zh) * 2021-08-16 2022-09-23 海南鑫开源医药科技有限公司 一种玻璃体腔内注射剂、其制备方法及应用
CN113520995B (zh) * 2021-08-16 2023-03-10 海南鑫开源医药科技有限公司 一种离子敏感型眼用原位凝胶、其制备方法及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63233939A (ja) * 1987-01-06 1988-09-29 アリゾナ　ボード　オブ　リーゼンツ コンブレタスタチン類
WO1999035150A1 (en) * 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Synthesis of combretastatin a-4 prodrugs and trans-isomers thereo f
WO2000048591A1 (en) * 1999-02-16 2000-08-24 Angiogene Pharmaceuticals Ltd. Combinations for the treatment of diseases involving angiogenesis
WO2000048606A1 (en) * 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
WO2002022626A1 (en) * 2000-09-14 2002-03-21 Bristol-Myers Squibb Company Combretastatin a-4 phosphate prodrug salts with nitrogen-containing compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63233939A (ja) * 1987-01-06 1988-09-29 アリゾナ　ボード　オブ　リーゼンツ コンブレタスタチン類
WO1999035150A1 (en) * 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Synthesis of combretastatin a-4 prodrugs and trans-isomers thereo f
WO2000048591A1 (en) * 1999-02-16 2000-08-24 Angiogene Pharmaceuticals Ltd. Combinations for the treatment of diseases involving angiogenesis
WO2000048606A1 (en) * 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
WO2002022626A1 (en) * 2000-09-14 2002-03-21 Bristol-Myers Squibb Company Combretastatin a-4 phosphate prodrug salts with nitrogen-containing compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532113A (ja) * 2009-07-02 2012-12-13 オキシジーン， インコーポレイテッド 後嚢混濁を予防するためのコンブレタスタチン
JP2013502440A (ja) * 2009-08-27 2013-01-24 バイオノミックス リミテッド 黄斑変性の治療

Also Published As

Publication number Publication date
EP1406600A1 (en) 2004-04-14
NZ575466A (en) 2011-01-28
CN1527704A (zh) 2004-09-08
WO2003006002A8 (en) 2004-05-27
WO2003006002A1 (en) 2003-01-23
EP1406600A4 (en) 2007-06-06
JP2009132738A (ja) 2009-06-18
CN1527704B (zh) 2011-05-18
KR20040030042A (ko) 2004-04-08
WO2003006002A9 (en) 2004-07-22
CA2453442C (en) 2011-02-01
CA2453442A1 (en) 2003-01-23
ZA200400210B (en) 2005-06-29

Similar Documents

Publication Publication Date Title
US20030181531A1 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
US10925889B2 (en) Method of treating, reducing, or alleviating a medical condition in a patient
US11648261B2 (en) Method of treating, reducing, or alleviating a medical condition in a patient
JP2009132738A (ja) 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法
RU2359693C2 (ru) Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний
TW200302226A (en) Methods for treating ocular neovascular diseases
US20100190734A1 (en) Method of treating dry eye disease with azithromycin
JP2004504271A (ja) Ｄｆｍｏのｄ−鏡像異性体およびその癌を処置するための使用方法
JP2005272464A (ja) 炎症の影響を低減するための組成物および物品
RU2354398C2 (ru) Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний
AU2008202468B2 (en) Compositions and Methods of Administering Tubulin Binding Agents for the Treatment of Ocular Diseases
WO2005004859A1 (en) Coumarin derivatives for the treatment of ophthalmic disorders
WO2001068076A2 (en) D-enantiomer of dfmo and methods of use thereof for treating cancer
AU2002322494A1 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
CN109789115A (zh) 用于治疗眼疾的方法
Kralinger et al. Intravitreal acetylsalicylic acid in silicone oil: pharmacokinetics and evaluation of its safety by ERG and histology
JP2005521681A (ja) 尿素および尿素誘導体を使用した眼科疾患の治療方法
JP2004331502A (ja) 視神経細胞保護剤
RU2303965C2 (ru) Способ лечения внутриглазных новообразований большого размера
WO2001056606A1 (en) Remedies for ophthalmic diseases
RU2458657C1 (ru) Способ торможения грубого рубцевания конъюнктивы
JP2004537533A (ja) 視神経細胞保護剤
Davies MALIGNANT TUMOURS OF EYE
Sorbera et al. LY-333531 Mesylate Hydrate
de Medicis Sajous Analytical Cyclopaedia of Practical Medicine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080918

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081215

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090116

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090316

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091029

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100112

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111031

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111130

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120105